Accurate, sensitive mass techniques required to identify specific peak of certain nitrosamines Viveka Roychowdhury May 29, 2020 Continuing its investigation into the presence of potential carcinogenic materials in various medicines, on May 28, the US FDA…
Carcinogens under the scan Viveka Roychowdhury Feb 3, 2020 As trace amounts of cancer causing contaminants continue to crop up in certain medicines, pharma companies are upgrading their…
After sartans and ranitidine, where will NDMA show up next? Viveka Roychowdhury Nov 1, 2019 While regulators and pharma companies try to understand if it is the product or the process that is at fault in the ranitidine…
